NSE BSE
suven pharmaceuticals ltd stock

SUVEN PHARMACEUTICALS LTD Share Price

- - (%)
Sector: -

17945

543064

SUVENPHAR

img img img img
No Data Available

SUVEN PHARMACEUTICALS LTD Share Price Update


As of the latest trading session, SUVEN PHARMACEUTICALS LTD share price is currently at 645.7, which is up by 1.54 from its previous closing. Today, the stock has fluctuated between 644.00 and 656.00. Over the past year, SUVEN PHARMACEUTICALS LTD has achieved a return of 35.61 %. In the last month alone, the return has been -0.96 %.

SUVEN PHARMACEUTICALS LTD Performance

Day Range

Low644.00 High656.00
645.70

52 Week Range

Low 469.45 High 768.00
645.70

Open Price

648.55

Prev. Close

644.15

Volume (Shares)

6841.00

Total traded value

44.17

Upper Circuit

676.35

Lower Circuit

611.95

Note: The current prices & values are delayed, Login to your account for live updates.

SUVEN PHARMACEUTICALS LTD Fundamentals


(Standalone)

Market Cap (Cr) 16437.26
PE Ratio (TTM) 42.85
Book Value / Share 76.53
Beta 0.50
ROE 26.46%
EPS (TTM) 14.99
Dividend Yield 0.93%
Net Profit Qtr (Cr) 52.36

SUVEN PHARMACEUTICALS LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars DEC 2023 (Values in Cr)
Revenue 212.83
Operating Expense 157.29
Net Profit 52.36
Net Profit Margin (%) 24.60
Earnings Per Share (EPS) 2.06
EBITDA 82.10
Effective Tax Rate (%) 24.66
Particulars SEP 2023 (Values in Cr)
Revenue 224.62
Operating Expense 138.25
Net Profit 74.73
Net Profit Margin (%) 33.26
Earnings Per Share (EPS) 2.94
EBITDA 111.55
Effective Tax Rate (%) 25.69
Particulars JUN 2023 (Values in Cr)
Revenue 344.03
Operating Expense 186.44
Net Profit 124.29
Net Profit Margin (%) 36.12
Earnings Per Share (EPS) 4.88
EBITDA 179.95
Effective Tax Rate (%) 25.85
Particulars MAR 2023 (Values in Cr)
Revenue 364.39
Operating Expense 202.67
Net Profit 130.16
Net Profit Margin (%) 35.71
Earnings Per Share (EPS) 5.11
EBITDA 185.39
Effective Tax Rate (%) 24.52
Particulars DEC 2022 (Values in Cr)
Revenue 348.49
Operating Expense 213.72
Net Profit 109.47
Net Profit Margin (%) 31.41
Earnings Per Share (EPS) 4.30
EBITDA 159.57
Effective Tax Rate (%) 25.67
Particulars MAR 2023 (Values in Cr)
Revenue 1330.08
Operating Expense 795.24
Net Profit 432.60
Net Profit Margin (%) 32.52
Earnings Per Share (EPS) 16.99
EBITDA 627.62
Effective Tax Rate (%) 25.33
Particulars MAR 2022 (Values in Cr)
Revenue 1320.22
Operating Expense 785.56
Net Profit 558.10
Net Profit Margin (%) 42.27
Earnings Per Share (EPS) 21.92
EBITDA 767.78
Effective Tax Rate (%) 22.74
Particulars MAR 2021 (Values in Cr)
Revenue 1009.72
Operating Expense 609.97
Net Profit 308.65
Net Profit Margin (%) 30.56
Earnings Per Share (EPS) 12.12
EBITDA 454.76
Effective Tax Rate (%) 25.44
Particulars MAR 2020 (Values in Cr)
Revenue 833.79
Operating Expense 494.31
Net Profit 270.08
Net Profit Margin (%) 32.39
Earnings Per Share (EPS) 21.21
EBITDA 399.76
Effective Tax Rate (%) 24.47
Particulars MAR 2019 (Values in Cr)
Revenue 377.83
Operating Expense 220.57
Net Profit 109.27
Net Profit Margin (%) 28.92
Earnings Per Share (EPS) 8.59
EBITDA 172.16
Effective Tax Rate (%) 30.77
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.16
ROE % 25.21
ROCE % 33.22
Total Debt to Total Equity 0.05
EBITDA Margin 46.28
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.99
ROE % 29.79
ROCE % 40.62
Total Debt to Total Equity 0.09
EBITDA Margin 48.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 46.38
ROE % 35.78
ROCE % 40.45
Total Debt to Total Equity 0.16
EBITDA Margin 50.61
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.37
ROE % 44.58
ROCE % 49.77
Total Debt to Total Equity 0.19
EBITDA Margin 54.10
Particulars MAR 2019 (Values in Cr)
Book Value / Share 0.00
ROE % 18.92
ROCE % 23.66
Total Debt to Total Equity 0.14
EBITDA Margin 45.56
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.72
ROE % 26.46
ROCE % 34.28
Total Debt to Total Equity 0.05
EBITDA Margin 47.74
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.74
ROE % 43.17
ROCE % 51.45
Total Debt to Total Equity 0.09
EBITDA Margin 58.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.84
ROE % 33.40
ROCE % 38.83
Total Debt to Total Equity 0.18
EBITDA Margin 45.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 61.50
ROE % 39.71
ROCE % 45.81
Total Debt to Total Equity 0.20
EBITDA Margin 48.32
Particulars MAR 2019 (Values in Cr)
Book Value / Share 0.00
ROE % 45.41
ROCE % 56.78
Total Debt to Total Equity 0.14
EBITDA Margin 45.56
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 68.01
Total Assets 1965.74
Total Liabilities 1965.74
Total Equity 1735.18
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 20.92
Return on Capital (%) 22.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.30
Total Assets 1829.58
Total Liabilities 1829.58
Total Equity 1527.18
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 24.80
Return on Capital (%) 27.97
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 1474.47
Total Liabilities 1474.47
Total Equity 1180.79
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 24.57
Return on Capital (%) 27.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 14.07
Total Assets 1172.81
Total Liabilities 1172.81
Total Equity 844.76
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 27.02
Return on Capital (%) 30.78
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 12.89
Total Assets 783.01
Total Liabilities 783.01
Total Equity 590.29
Share Outstanding 127282478
Price to Book Ratio 0.00
Return on Assets (%) 13.95
Return on Capital (%) 16.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 46.23
Total Assets 1958.33
Total Liabilities 1958.33
Total Equity 1749.38
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 22.09
Return on Capital (%) 23.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 32.95
Total Assets 1804.88
Total Liabilities 1804.88
Total Equity 1520.69
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 30.92
Return on Capital (%) 34.53
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 1358.82
Total Liabilities 1358.82
Total Equity 1065.18
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 22.71
Return on Capital (%) 25.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 13.95
Total Assets 1110.88
Total Liabilities 1110.88
Total Equity 782.82
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 24.31
Return on Capital (%) 27.9
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 0.00
Total Liabilities 0.00
Total Equity -0.01
Share Outstanding 100000
Price to Book Ratio 0.00
Return on Assets (%) -266.05
Return on Capital (%) 1082.37
Particulars MAR 2023 (Values in Cr)
Net Income 559.72
Cash from Operations 596.70
Cash from Investing -194.84
Cash from Financing -235.83
Net change in Cash 20.23
Free Cash Flow 882.47
Particulars MAR 2022 (Values in Cr)
Net Income 667.58
Cash from Operations 514.25
Cash from Investing -136.13
Cash from Financing -156.48
Net change in Cash 37.38
Free Cash Flow 589.44
Particulars MAR 2021 (Values in Cr)
Net Income 467.67
Cash from Operations 491.98
Cash from Investing -311.39
Cash from Financing -75.66
Net change in Cash -4.51
Free Cash Flow 602.82
Particulars MAR 2020 (Values in Cr)
Net Income 404.51
Cash from Operations 493.32
Cash from Investing -413.44
Cash from Financing 7.32
Net change in Cash 0.79
Free Cash Flow 596.39
Particulars MAR 2019 (Values in Cr)
Net Income 157.86
Cash from Operations 83.46
Cash from Investing -65.47
Cash from Financing 25.97
Net change in Cash 10.90
Free Cash Flow 140.25
Particulars MAR 2023 (Values in Cr)
Net Income 579.39
Cash from Operations 629.96
Cash from Investing -235.57
Cash from Financing -235.78
Net change in Cash 12.81
Free Cash Flow 774.56
Particulars MAR 2022 (Values in Cr)
Net Income 722.44
Cash from Operations 421.63
Cash from Investing -90.29
Cash from Financing -156.48
Net change in Cash 23.11
Free Cash Flow 496.82
Particulars MAR 2021 (Values in Cr)
Net Income 413.97
Cash from Operations 438.27
Cash from Investing -257.65
Cash from Financing -75.66
Net change in Cash -4.48
Free Cash Flow 549.11
Particulars MAR 2020 (Values in Cr)
Net Income 357.59
Cash from Operations 445.15
Cash from Investing -366.64
Cash from Financing 8.57
Net change in Cash 0.67
Free Cash Flow 548.22
Particulars MAR 2019 (Values in Cr)
Net Income -0.02
Cash from Operations -0.01
Cash from Investing 0.00
Cash from Financing 0.01
Net change in Cash 0.00
Free Cash Flow -0.01
Company Name Price P/E P/B Market Cap 52 Week Low/High
SUVEN PHARMACEUTICALS LTD 642.35 44.09 8.44 16351.98 427.05 / 767.00
BLISS GVS PHARMA LTD 109.55 11.97 1.18 1146.89 71.00 / 148.95
CIPLA LTD 1399.35 26.53 4.23 112982.81 911.80 / 1519.00
FERMENTA BIOTECH LIMITED 161.20 0.00 1.65 474.43 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 2291.55 56.12 21.83 38820.24 1265.00 / 2649.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
SUVEN PHARMACEUTICALS LTD 642.35 42.85 8.39 16351.98 427.05 / 767.00
AMRUTAJAN HEALTH LTD 743.50 48.85 8.20 2149.51 556.05 / 802.60
ASTRAZENECA PHARMA IND LT 5757.75 90.25 21.97 14394.38 3131.10 / 7208.00
BLISS GVS PHARMA LTD 109.55 15.13 1.16 1146.89 71.00 / 148.95
ABBOTT INDIA LIMITED 26490.20 46.86 15.21 56291.68 20594.25 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 647.00
  • 26 Days 648.20
  • 10 Days 653.30
  • 50 Days 654.70
  • 12 Days 653.20
  • 100 Days 658.90
  • 20 Days 652.70
  • 200 Days 512.80
641.88
PIVOT
First Resistance 651.77
Second Resistance 659.38
Third Resistance 669.27
First Support 634.27
Second Support 624.38
Third Support 616.77
RSI 41.91
MACD 5.04
Commodity Channel Index (CCI) -85.20
ADX 7.88
Williams % R -72.88

Over 1 Month

down

-0.96

Over 3 Months

down

-4.30

Over 6 Months

down

11.07

Over 1 Year

down

35.61

Over 3 Years

down

6.69

Over 5 Years

down

30.75

SUVEN PHARMACEUTICALS LTD Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

SUVEN PHARMACEUTICALS LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
25.09
Promoter Holdings
50.1
FII
9.54
DII
15.26
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Berhyanda Limited Shareholding of Promoter and Promoter Group 1.27539592E8 50.1
Jasti Property And Equity Holdings Private Limited (initscapacityassoletrusteeofjastifamilytrust) Public Shareholding 2.5192957E7 9.9
Dsp Equity Savings Fund Public Shareholding 1.5057148E7 5.91
Uti-unit Linked Insurance Plan Public Shareholding 9572199.0 3.76
Hsbc Midcap Fund Public Shareholding 3990865.0 1.57
Goldman Sachs Funds - Goldman Sachs India Equity P Public Shareholding 2830570.0 1.11

SUVEN PHARMACEUTICALS LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2022-09-09 1.0 Interim 2022-09-12 Equity shares 2022-09-09 5.0 Special 2022-09-12 Equity shares 2022-05-13 1.0 Interim 2 2022-05-17 Equity shares 2022-05-13 1.0 Special 2022-05-17 Equity shares 2022-02-15 1.0 Interim 2022-02-16 Equity shares 2022-02-15 2.0 Special 2022-02-16 Equity shares 2021-08-13 1.0 Final 2021-08-17 Equity shares 2021-02-17 1.0 Interim 2021-02-18 Equity shares
Ex-Date Ex-Bonus Ratio
2020-09-28 2020-09-25 1:1
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About SUVEN PHARMACEUTICALS LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by SUVEN PHARMACEUTICALS LTD

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Suven Pharmaceuticals Ltd?

Answer Field

The share price of Suven Pharmaceuticals Ltd for NSE is ₹ 645.7 and for BSE is ₹ 645.

What is the Market Cap of Suven Pharmaceuticals Ltd?

Answer Field

The market cap of Suven Pharmaceuticals Ltd for NSE is ₹ 16,437.26 Cr. and for BSE is ₹ 16,419.44 Cr. as of now.

What is the 52 Week High and Low of Suven Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Suven Pharmaceuticals Ltd for NSE is ₹ 768.00 and ₹ 469.45 and for BSE is ₹ 767.00 and ₹ 427.05.

How to Buy Suven Pharmaceuticals Ltd share?

Answer Field

You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Suven Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 35.61%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users

icon-with-text

4.3 App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3800 Cr MTF Book

icon-with-text
loader